STOCK TITAN
  1. Home
  2. News
  3. NVRO

Nevro Corp - NVRO STOCK NEWS

Welcome to our dedicated news page for Nevro (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nevro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nevro's position in the market.

News
Nevro Announces Acquisition of Vyrsa™ Technologies
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) refinances with a $200M structured debt maturing in 2029, acquires Vyrsa Technologies, and closes a $200 million term loan credit facility. Vyrsa is projected to be accretive to Nevro in 2024 for both revenue and AEBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.66%
Tags
acquisition
-
News
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) - Nevro Corp. announces the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine. The data show that patients in the high-frequency SCS arm experienced profound improvements in pain, function, and quality of life, plus reduced opioid use compared to the CMM arm at 24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
Rhea-AI Summary
Nevro Corp. reported its third quarter 2023 financial results, with worldwide revenue of $103.9 million, a 3% growth compared to the same period last year. Painful Diabetic Neuropathy (PDN) indication sales grew 56% to approximately $20.8 million. The company provided fourth quarter revenue guidance of $108 million to $110 million and updated its full-year 2023 revenue guidance to $417 million to $419 million, representing 3% constant currency growth over 2022. The net loss from operations in the third quarter was $25.6 million, and the non-GAAP adjusted EBITDA loss was $5.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
earnings
News
Nevro to Report Third Quarter 2023 Financial Results
Rhea-AI Summary
Nevro Corp. to report Q3 2023 financial results on Nov 1, 2023. Conference call scheduled at 1:30 pm PT/ 4:30 pm ET. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences earnings
-
News
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
Rhea-AI Summary
Nevro Corp. announces publication of data validating the health economic benefits of 10 kHz Therapy for chronic pain treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News
Nevro Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Nevro Corp. to present at Wells Fargo Healthcare Conference and Morgan Stanley Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
News
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Rhea-AI Summary
Nevro Corp. announces publication of 24-month data from SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial, showing long-term efficacy of high-frequency 10 kHz SCS in treating PDN. Patients experienced durable pain relief, improved quality of life, and better sleep. Neurological symptoms also improved. The study confirms the safety and effectiveness of 10 kHz SCS as a therapy for PDN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
News
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
Rhea-AI Summary
Nevro Corp. reported second quarter 2023 financial results, with worldwide revenue of $108.8 million, a 4% increase compared to the same period in 2022. Painful Diabetic Neuropathy (PDN) indication sales grew 73% to approximately $19.0 million. The company also provided third quarter revenue guidance of $95 million to $97 million and updated its full-year 2023 revenue guidance to $410 million to $415 million, representing 1% to 2% constant currency growth over 2022. Additionally, Nevro announced the appointment of Greg Siller as the new Chief Commercial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.69%
Tags
earnings
-
News
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
Rhea-AI Summary
Nevro Corp. will present 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT) and the SENZA Non-Surgical Refractory Back Pain (NSRBP) RCT at the ASPN Fifth Annual Conference. They will also showcase their HFX™ platform of SCS solutions, including HFX iQ™, an AI-based system that learns from patients to optimize pain relief and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
News
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Summary
Nevro Corp. announced that its CEO and CFO will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. A webcast and archived recording will be available on Nevro's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences
Stock NVRO logo
Nevro Corp

NYSE:NVRO

NVRO Rankings

#3015 Ranked by Market Cap
#4959 Ranked by Stock Gains
N/A Ranked by Dividends

NVRO Stock Data

481.54M
35.44M
3.91%
108.64%
11.54%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About NVRO

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.